AveXis, Inc. (AVXS) Just Reaches 52-Week High?

March 11, 2018 - By Henry Gaston

The stock of AveXis, Inc. (NASDAQ:AVXS) hit a new 52-week high and has $145.15 target or 6.00 % above today’s $136.93 share price. The 8 months bullish chart indicates low risk for the $5.03B company. The 1-year high was reported on Mar, 11 by Barchart.com. If the $145.15 price target is reached, the company will be worth $301.74 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 2.26% or $3.03 during the last trading session, reaching $136.93. About 422,973 shares traded. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since March 11, 2017 and is uptrending. It has outperformed by 79.15% the S&P500.

Analysts await AveXis, Inc. (NASDAQ:AVXS) to report earnings on March, 15. They expect $-1.51 earnings per share, down 64.13 % or $0.59 from last year’s $-0.92 per share. After $-1.52 actual earnings per share reported by AveXis, Inc. for the previous quarter, Wall Street now forecasts -0.66 % EPS growth.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. The stock of AveXis, Inc. (NASDAQ:AVXS) has “Buy” rating given on Friday, May 13 by Goldman Sachs. The rating was maintained by Jefferies on Monday, September 19 with “Buy”. Bank of America initiated the shares of AVXS in report on Friday, October 21 with “Buy” rating. Jefferies upgraded AveXis, Inc. (NASDAQ:AVXS) on Friday, August 12 to “Buy” rating. The firm earned “Market Perform” rating on Friday, July 15 by Wells Fargo.

More important recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Globenewswire.com which released: “AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results” on February 20, 2018, also Nasdaq.com published article titled: “AveXis Reaches Analyst Target Price”, Streetinsider.com published: “Form 4 AveXis, Inc. For: Mar 01 Filed by: Knudten Andrew F.” on March 05, 2018. More interesting news about AveXis, Inc. (NASDAQ:AVXS) was released by: Globenewswire.com and their article: “AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results” with publication date: February 27, 2018.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $5.03 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.